Daily Sepsis Research Analysis
Three standout sepsis studies advance therapy, risk stratification, and antimicrobial policy. A mechanistic peptide (sHVF18) shows that dual targeting of LPS and CD14 is essential for survival benefit in polymicrobial sepsis; EASIX robustly stratifies mortality risk in SA-AKI across two ICU databases; and a multicenter Southeast Asian analysis details gram-negative dominance and high resistance in neonatal bloodstream infections.
Summary
Three standout sepsis studies advance therapy, risk stratification, and antimicrobial policy. A mechanistic peptide (sHVF18) shows that dual targeting of LPS and CD14 is essential for survival benefit in polymicrobial sepsis; EASIX robustly stratifies mortality risk in SA-AKI across two ICU databases; and a multicenter Southeast Asian analysis details gram-negative dominance and high resistance in neonatal bloodstream infections.
Research Themes
- Dual-target immunotherapy for sepsis (LPS and CD14)
- Endothelial stress–based risk stratification in SA-AKI
- Neonatal sepsis epidemiology and antimicrobial resistance in Southeast Asia
Selected Articles
1. The conserved N-terminal histidine in an engineered peptide mediates sepsis treatment efficacy via dual binding to CD14 and LPS.
sHVF18 requires a conserved N-terminal histidine to bind CD14 while retaining LPS binding; this dual targeting is critical for survival benefit in polymicrobial sepsis. K-substitution improves LPS interactions but disrupts CD14 binding, abolishing efficacy beyond endotoxemia.
Impact: Defines a mechanistic requirement—dual LPS and CD14 engagement—for therapeutic efficacy in clinically relevant polymicrobial sepsis models, guiding peptide design principles.
Clinical Implications: Supports development of multivalent innate immune modulators that target both pathogen-associated molecules and host receptors; single-target anti-LPS agents may fail in polymicrobial sepsis.
Key Findings
- Dual binding to LPS and the CD14 groove is essential for in vivo efficacy in polymicrobial sepsis.
- The conserved N-terminal histidine mediates CD14 interactions; K substitution disrupts CD14 binding and abolishes efficacy in polymicrobial sepsis.
- R variants retain weaker CD14 affinity (likely via cation–π interactions) and partial function.
- sHVF18 reduced inflammation and improved survival in polymicrobial sepsis, whereas K-variant efficacy was limited to LPS shock.
Methodological Strengths
- Integrated evolutionary analysis, in silico modeling, and structure–function mutagenesis with two in vivo sepsis models.
- Direct comparison of peptide variants across endotoxemia and polymicrobial sepsis establishes context-dependent efficacy.
Limitations
- Preclinical models; no human pharmacokinetic or safety data.
- Potential differences in CD14/LPS dynamics between murine models and human sepsis.
Future Directions: Optimize peptide chemistry for stability and pharmacokinetics, test combination with antibiotics, and initiate phase I safety studies with biomarker-guided enrichment.
Sepsis remains a major clinical challenge due to the limited efficacy of existing therapies in controlling excessive inflammation. The engineered stapled peptide sHVF18, derived from an evolutionarily conserved thrombin innate fold, binds both lipopolysaccharide (LPS) and the LPS-binding groove of CD14, enabling dual targeting of bacterial components and host immune signaling. To define structural prerequisites for this dual action, we combined evolutionary analysis, in silico modeling, and experimental methods. Substituting the N-terminal histidine with lysine (K) or arginine (R) improved solubility, reduced aggregation, and enhanced interactions with LPS. However, unexpectedly, K substitutions impaired CD14 binding, whereas R variants retained weaker affinity, possibly through cation-π interactions. The essential role of the evolutionarily conserved N-terminal histidine for CD14 interactions and therapeutic efficacy was demonstrated using LPS-induced shock and polymicrobial sepsis models. While the K variant exhibited superior efficacy in LPS-induced shock, its disrupted CD14 interactions rendered it ineffective in polymicrobial sepsis. In contrast, sHVF18, by engaging both LPS and CD14, effectively reduced inflammation and improved survival in polymicrobial sepsis. These findings highlight that targeting of both LPS and CD14 is essential for therapeutic efficacy, underscoring multivalency as a key principle for future sHVF18-based sepsis therapeutics.
2. Endothelial Activation and Stress Index Elevation Associated with Adverse Prognosis in Sepsis-associated acute kidney injury Patients: Validation Based on Two Critical Care Cohorts.
In 12,267 SA-AKI patients, EASIX showed a non-linear relationship with 28-day mortality, with worse outcomes above an inflection point of 10.83. Findings were robust across PSM/weighting, outperformed SOFA for short-term mortality prediction, and were externally validated in eICU.
Impact: Provides a pragmatic, externally validated prognostic index tied to endothelial stress that can refine risk stratification beyond SOFA in SA-AKI.
Clinical Implications: EASIX can be integrated into ICU workflows to identify high-risk SA-AKI patients for closer monitoring, early nephrology input, and enrollment in trials targeting endothelial dysfunction.
Key Findings
- EASIX displayed a non-linear association with 28-day mortality with an inflection point at 10.83.
- High EASIX was associated with higher 28-day, in-hospital, and ICU mortality after PSM (all P < 0.001).
- EASIX outperformed SOFA and traditional covariates in ROC analyses for 28-day mortality.
- Results were replicated in an independent eICU cohort, supporting external validity.
Methodological Strengths
- Large multicenter ICU dataset (MIMIC-IV) with extensive causal inference techniques (PSM, IPTW, overlap weighting).
- External validation in eICU and multiple sensitivity analyses (subgroups, E-values) strengthen robustness.
Limitations
- Retrospective design limits causal inference and is susceptible to residual confounding.
- EASIX thresholds and timing of measurement for clinical implementation require prospective validation.
Future Directions: Prospective, multi-ICU implementation studies to define actionable EASIX thresholds and assess impact on care pathways and outcomes.
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a prevalent complication in critical care settings with high mortality. Early identification of high-risk patients is crucial. The Endothelial Activation Stress Index (EASIX) has been studied in other conditions but not in SA-AKI. This study evaluates EASIX's association with short-term mortality in SA-AKI patients. METHODS: In this retrospective cohort study, data from 12,267 SA-AKI patients in MIMIC-IV were analyzed. EASIX was categorized using curve fitting and inflection point analysis. Propensity score matching (PSM), overlap weighting (OW), pair algorithm (PA), and inverse probability of treatment weight (IPTW) ensured data balance. Cox models, Kaplan-Meier analysis, subgroup analyses, ROC Curves and E-value assessments were used to examine the relationship between EASIX and outcomes. Furthermore, we validated these findings using the eICU database. RESULTS: A non-linear association between EASIX and 28-day mortality was found, with an inflection point at 10.83. PSM balanced covariates. Kaplan-Meier analysis showed significantly lower survival in the high EASIX group (P < 0.001 pre-PSM, P = 0.002 post-PSM). Post-PSM, the high EASIX group had higher 28-day mortality (42.9% vs. 32.9%), in-hospital mortality (40.5% vs. 30.8%), and ICU mortality (29.6% vs. 20.4%; all P < 0.001). Multivariable regression and weighting methods (IPTW, PA, OW) confirmed the increased mortality risk. Subgroup and E-value analyses further validated these findings. ROC analysis yielded an AUC for 28-day mortality, outperforming SOFA and other traditional covariates. External validation in the eICU database confirmed similar performance. CONCLUSION: EASIX is a reliable prognostic indicator for short-term mortality in SA-AKI patients. Elevated EASIX levels are associated with increased mortality risk. Future research should explore its clinical utility in risk stratification for SA-AKI.
3. Pathogen distribution and antimicrobial resistance among neonatal bloodstream infections in Southeast Asia: results from NeoSEAP, a multicentre retrospective study.
Across 10 sites in five countries, gram-negative organisms accounted for 78.4% of neonatal sepsis pathogens, with high non-susceptibility to commonly used antibiotics. These multicenter data provide urgently needed AMR surveillance to inform empiric therapy and infection control in Southeast Asian neonatal units.
Impact: Fills a critical regional data gap by providing multicenter AMR patterns in neonatal sepsis, directly informing empiric therapy and stewardship.
Clinical Implications: Suggests revisiting empiric antibiotic choices in neonatal sepsis (e.g., coverage for resistant gram-negatives), and strengthening infection prevention resources and stewardship programs.
Key Findings
- Among 14,804 neonatal blood cultures, 2,131 positives were identified, including 1,483 significant pathogens.
- Gram-negative bacteria predominated (78.4%; 1,163/1,483) as causes of neonatal sepsis.
- High non-susceptibility to commonly prescribed antibiotics across sites, highlighting challenges for empiric therapy.
- Data collected on infection prevention/control resources and prescribing practices enable context-specific stewardship.
Methodological Strengths
- Multicenter design spanning 10 sites in five countries with clustering-adjusted pooled estimates.
- Standardized extraction from laboratory records over a defined two-year period.
Limitations
- Retrospective design limits control of confounders and case adjudication.
- Clinical outcomes and detailed resistance mechanisms were not fully delineated in the abstract.
Future Directions: Prospective surveillance linking microbiology to outcomes, molecular resistance profiling, and interventional studies on stewardship and infection control.
BACKGROUND: Progress in reducing morbidity and mortality due to neonatal sepsis has slowed in recent decades and is threatened by the global rise of antimicrobial resistance. The populous Southeast Asian region has a high burden of both neonatal sepsis and antimicrobial resistance (AMR). Despite this, there remains a lack of robust data on the epidemiology of neonatal sepsis and the prevalence of AMR within the region. METHODS: We evaluated positive blood cultures and susceptibility profiles responsible for neonatal sepsis across 10 clinical sites in five countries in South and Southeast Asia (Sri Lanka, Indonesia, The Philippines, Malaysia, and Vietnam). Retrospective data on all blood cultures collected from neonates over two years (1st January 2019-31st December 2020) were extracted from laboratory records. Data were also collected on the availability and implementation of infection prevention and control resources, and antimicrobial prescribing practices. Pooled estimates across sites and pathogens were generated, with adjustment for clustering. FINDINGS: Of 14,804 blood cultures collected over the study period, a total of 2131 positive isolates (including 1483 significant pathogens) were identified. Gram-negative bacteria predominated as causative of neonatal sepsis (78·4%; 1163/1483) with INTERPRETATION: Neonatal sepsis in tertiary hospitals in Southeast Asia is predominantly caused by gram-negative bacteria, with high rates of non-susceptibility to commonly prescribed antibiotics. FUNDING: This study was supported by an Australian National Health and Medical Research Council (NHMRC) grant. The NHMRC was not involved in the design or conduct of the research.